Health Canada Study reports [Regulatives / Guidelines]

posted by anky1212 – India, 2019-02-21 05:05  – Posting: # 19951
Views: 611

Dear All,

As per Health canada guidance document, "To avoid study bias, comparative bioavailability studies should be conducted in such a way that the subjects are not aware of which product (test or reference) is being administered. Furthermore, the persons checking for adverse reactions and those conducting the bioanalysis of samples should not know the treatment sequence."

In this case, if adverse events is ongoing, analysis both analytical and statistical phase completed, shall we submit treatment or code in study report?

Upto which phase guidance is applicable?

After completion of statistical phase if adverse event is still ongoing, still we need to follow guidance?

Thanks
Ankur Patel

Complete thread:

Activity
 Admin contact
20,138 posts in 4,246 threads, 1,386 registered users;
online 2 (0 registered, 2 guests [including 2 identified bots]).
Forum time (Europe/Vienna): 17:43 CET

It is better to debate a question without settling it
than to settle a question without debating it.    Joseph Joubert

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5